Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Nvo save search
Cytoki Pharma Presents Preclinical Data Demonstrating Weight Reduction and Improved Glucose Control with Lipidated IL-22 at ObesityWeek 2023
Published: 2023-10-16 (Crawled : 19:00) - biospace.com/
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: -0.84%
H: 0.19%
C: -0.13%
il-22 obesityweek pharma control preclinical
Novo Nordisk A/S – Share repurchase programme
Published: 2023-10-16 (Crawled : 12:00) - globenewswire.com
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: -0.84%
H: 0.19%
C: -0.13%
repurchase
Novo Nordisk to acquire ocedurenone for uncontrolled hypertension from KBP Biosciences
Published: 2023-10-16 (Crawled : 11:00) - globenewswire.com
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: -0.84%
H: 0.19%
C: -0.13%
acquire hypertension
Novo Nordisk raises sales and operating profit outlook for 2023
Published: 2023-10-13 (Crawled : 13:00) - globenewswire.com
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: 1.41%
H: 2.37%
C: 0.54%
sales
Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis
Published: 2023-10-10 (Crawled : 21:00) - globenewswire.com
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: 3.75%
H: 2.82%
C: 2.42%
kidney
The Evolving Market Dynamics of Factor-based Bleeding Disorders: Hemophilia A, Hemophilia B, and Von Willebrand Disease | Key Analysis by DelveInsight
Published: 2023-10-09 (Crawled : 21:00) - prnewswire.com
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: 0.09%
H: 1.41%
C: 0.94%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.67%
H: 0.56%
C: -0.01%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.51%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.48%
H: 1.39%
C: 0.51%
ALPN | $64.57 0.03% 0.03% 1.2M
|
Health Technology
|
| O: -1.07%
H: 0.0%
C: -6.9%
bleeding disease market
Novo Nordisk A/S - share repurchase programme
Published: 2023-10-09 (Crawled : 11:00) - globenewswire.com
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: -1.07%
H: 1.15%
C: 1.02%
repurchase
Global Diet Pills Market Research Report 2023: Market is Expected to Reach $ 2.47 Billion in 2027 - Focus on Xenical, Qsymia, Saxenda, Diethylpropion, Liraglutide, and Phentermine
Published: 2023-10-05 (Crawled : 10:00) - prnewswire.com
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: -0.08%
H: 1.44%
C: 1.15%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: -0.39%
H: 0.72%
C: 0.61%
report expected reach research global market
Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic®, Wegovy®, or Mounjaro®, to Optimize Weight Loss by Preventing Muscle Wasting and Further Increasing Fat Loss in a Phase 2b Obesity Clinical Study
Published: 2023-10-04 (Crawled : 13:00) - globenewswire.com
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: 1.88%
H: 0.59%
C: -0.44%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -2.39%
H: 0.0%
C: 0.0%
VERU | $1.325 3.92% 3.77% 1.5M
|
Health Technology
|
| O: 6.22%
H: 1.26%
C: -6.19%
ozempic obesity study
Notice of Extraordinary General Meeting in Orexo AB (publ)
Published: 2023-10-03 (Crawled : 09:00) - prnewswire.com
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: -2.4%
H: 0.22%
C: -2.03%
meeting
FDA approves Rivfloza™ for children ≥9 years old and adults living with primary hyperoxaluria type 1 (PH1), a rare genetic condition
Published: 2023-10-02 (Crawled : 17:00) - biospace.com/
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: -0.85%
H: 3.13%
C: 1.81%
fda rare children genetic living
Novo Nordisk A/S - share repurchase programme
Published: 2023-10-02 (Crawled : 12:00) - globenewswire.com
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: -0.85%
H: 3.13%
C: 1.81%
repurchase
Global Bleeding Disorders Market Set to Surge, Expected to Reach $25.97 Billion by 2032 with a 6.6% CAGR
Published: 2023-09-27 (Crawled : 02:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.69%
H: 0.0%
C: 0.0%
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.56%
H: 0.06%
C: -0.62%
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: -0.51%
H: 0.62%
C: 0.42%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: 0.0%
GRFS | $6.4 -1.23% -1.25% 960K
|
Health Technology
|
| O: -0.22%
H: 1.09%
C: -0.55%
bleeding expected reach disorders global set market
Atherosclerotic Cardiovascular Disease Market to Observe Impressive Growth at a CAGR of 2.2% by 2032, Predicts DelveInsight
Published: 2023-09-26 (Crawled : 21:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.69%
H: 0.0%
C: 0.0%
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: -0.51%
H: 0.62%
C: 0.42%
BSX | $72.91 5.68% -0.03% 15M
|
Health Technology
|
| O: -0.09%
H: 0.72%
C: -1.29%
SLN | $22.33 -0.8% -0.81% 110K
|
Health Technology
|
| O: -1.3%
H: 2.44%
C: -1.42%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: 0.0%
MESO | $6.21 3.5% 3.38% 200K
|
Health Technology
|
| O: 3.25%
H: 1.57%
C: -3.15%
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
|
| O: 0.99%
H: 2.09%
C: 0.83%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: 1.0%
H: 0.69%
C: -1.01%
disease cardiovascular growth market
Acesion Pharma Closes Oversubscribed €45M Series B Financing Round to Advance Development of Novel Therapy for Atrial Fibrillation
Published: 2023-09-26 (Crawled : 06:00) - prnewswire.com
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: 1.81%
H: 0.2%
C: -1.07%
pharma series therapy
Novo Nordisk A/S - share repurchase programme
Published: 2023-09-25 (Crawled : 15:00) - globenewswire.com
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: -0.44%
H: 0.33%
C: 0.25%
repurchase
Valo Health and Novo Nordisk to collaborate to discover and develop novel treatments for cardiometabolic diseases using human data and artificial intelligence
Published: 2023-09-25 (Crawled : 12:00) - globenewswire.com
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: -0.44%
H: 0.33%
C: 0.25%
health
Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.
Published: 2023-09-21 (Crawled : 13:30) - globenewswire.com
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: -1.92%
H: 0.61%
C: -1.74%
acquisition
Novo Nordisk and UNICEF to extend joint initiative to prevent global childhood obesity
Published: 2023-09-20 (Crawled : 19:00) - globenewswire.com
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: -1.92%
H: 0.61%
C: -1.74%
obesity initiative global
OnKure Therapeutics Appoints Ann Howell, Pharm.D., as Vice President of Regulatory Affairs
Published: 2023-09-20 (Crawled : 17:00) - biospace.com/
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: 1.26%
H: 1.82%
C: 0.03%
therapeutics
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.